Hunter Hutchinson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hunter Hutchinson has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
- Brandon Lucke-Wold
Department of Neurosurgery, University of Arizona, Tucson, AZ 85721, USA
8 shared publications - Brian L. Hoh
University of Florida College of Medicine
4 shared publications - Danyas Sarathy
Department of Neurosurgery, University of Florida, Gainesville, FL 32608, USA
4 shared publications - Matthew John Koch
Department of Neurosurgery, University of Florida, Gainesville, Florida, USA
4 shared publications - Zachary A. Sorrentino
Department of Neurosurgery, University of Florida College of Medicine, Gainesville, Florida, USA
4 shared publications - Abanob George Hanna
College of Medicine, University of Florida, Gainesville, FL 32610, USA
2 shared publications
Latest Publications
- Open Access
- 6 October 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (19)
Adropin Reduces Early Brain Injury and Delayed Cerebral Ischemia After Severe Subarachnoid Hemorrhage in a Mouse Model
Background: Delayed cerebral ischemia remains a major cause of morbidity after aneurysmal subarachnoid hemorrhage (SAH), and effective therapies beyond nimodipine are lacking. Adropin, an endogenous peptide that regulates endothelial function and nitric oxide signaling, has shown neurovascular protective effects in experimental SAH. However, its efficacy when administered at clinically relevant delayed time points and in severe SAH remains unclear. Methods: A severe double‐injection SAH model was induced in male C57BL/6 mice. Synthetic adropin or vehicle was administered beginning 6 or 12 hours after SAH, with repeat dosing according to experimental end points. Outcomes included eNOS (endothelial nitric oxide synthase) signaling, blood–brain barrier integrity, cerebral vasospasm, microvascular thrombosis, neuronal apoptosis, and neurobehavioral performance. Additional studies were conducted in energy homeostasis–associated knockout mice and tamoxifen‐induced brain endothelial‐specific adropin deletion. Statistical analyses were performed using Prism 10. Results: Endogenous adropin expression and eNOS signaling were reduced 24 hours after SAH. Adropin administration restored total eNOS expression. Adropin preserved tight junction integrity, selectively restoring occludin expression, and significantly reduced microvascular thrombosis. When administered 6 hours after SAH, adropin attenuated delayed cerebral vasospasm, reduced neuronal apoptosis, improved recognition memory and mitigated anxiety‐like behavior at 1 month post SAH. In contrast, adropin administered 12 hours after SAH conferred partial and inconsistent behavioral benefit and did not significantly reverse vasospasm. Adropin attenuated vasospasm and improved behavioral outcomes in energy homeostasis–associated knockout mice. Endothelial‐specific adropin deletion did not exacerbate vasospasm, and systemic adropin administration did not further improve vessel diameter in this model. Conclusions: Adropin confers robust neurovascular protection after severe SAH when administered within a clinically relevant early therapeutic window. These findings highlight adropin as a promising candidate for mitigating endothelial dysfunction, vasospasm, and long‐term neurological deficits following SAH, with timing of intervention playing a critical role in therapeutic efficacy.
- 6 October 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (19)
Open AccessAdropin Reduces Early Brain Injury and Delayed Cerebral Ischemia After Severe Subarachnoid Hemorrhage in a Mouse Model
Background: Delayed cerebral ischemia remains a major cause of morbidity after aneurysmal subarachnoid hemorrhage (SAH), and effective therapies beyond nimodipine are lacking. Adropin, an endogenous peptide that regulates endothelial function and nitric oxide signaling, has shown neurovascular protective effects in experimental SAH. However, its efficacy when administered at clinically relevant delayed time points and in severe SAH remains unclear. Methods: A severe double‐injection SAH model was induced in male C57BL/6 mice. Synthetic adropin or vehicle was administered beginning 6 or 12 hours after SAH, with repeat dosing according to experimental end points. Outcomes included eNOS (endothelial nitric oxide synthase) signaling, blood–brain barrier integrity, cerebral vasospasm, microvascular thrombosis, neuronal apoptosis, and neurobehavioral performance. Additional studies were conducted in energy homeostasis–associated knockout mice and tamoxifen‐induced brain endothelial‐specific adropin deletion. Statistical analyses were performed using Prism 10. Results: Endogenous adropin expression and eNOS signaling were reduced 24 hours after SAH. Adropin administration restored total eNOS expression. Adropin preserved tight junction integrity, selectively restoring occludin expression, and significantly reduced microvascular thrombosis. When administered 6 hours after SAH, adropin attenuated delayed cerebral vasospasm, reduced neuronal apoptosis, improved recognition memory and mitigated anxiety‐like behavior at 1 month post SAH. In contrast, adropin administered 12 hours after SAH conferred partial and inconsistent behavioral benefit and did not significantly reverse vasospasm. Adropin attenuated vasospasm and improved behavioral outcomes in energy homeostasis–associated knockout mice. Endothelial‐specific adropin deletion did not exacerbate vasospasm, and systemic adropin administration did not further improve vessel diameter in this model. Conclusions: Adropin confers robust neurovascular protection after severe SAH when administered within a clinically relevant early therapeutic window. These findings highlight adropin as a promising candidate for mitigating endothelial dysfunction, vasospasm, and long‐term neurological deficits following SAH, with timing of intervention playing a critical role in therapeutic efficacy.
- Open Access
- 1 July 2026
- Published by Wolters Kluwer Health in Stroke: Vascular and Interventional Neurology
- Vol. 6 (4)
Mechanical Thrombectomy for Pediatric Acute Ischemic Stroke With Large Vessel Occlusion: Technical Guide and Case Series
BACKGROUND: Pediatric acute ischemic stroke is a rare entity, and mechanical thrombectomy (MT) in this population can be technically challenging. We aim to discuss key technical aspects of pediatric MT and report our experience in this population. METHODS: Pediatric patients were identified from our prospectively maintained database of MT patients. Inclusion criteria were pediatric patients’ age >28 days and <18 years undergoing MT for large vessel occlusion at a single center between 2012 and 2023. RESULTS: Seven patients were included in this case series. Patient age ranged from ≈1 to 17 (10.0±6.2) years. Causes of large vessel occlusion included hypercoagulability disorders, cardiac disorders, and iatrogenic during neurointerventions. Most patients (n=5, 71.4%) had middle cerebral artery or internal carotid artery occlusions. Six patients (85.7%) were successfully treated with MT, achieving modified Thrombolysis in Cerebral Infarction grade 2C or above. Five patients were treated with stent retriever MT and the other 2 patients with aspiration MT alone, with an average of 2.3±1.5 passes total. Five patients (71.4%) made an excellent clinical recovery with a pediatric modified Rankin Scale score ≤2 at last outpatient follow-up (pediatric modified Rankin Scale score, 1.8±1.2). Average follow-up duration was 2.7±2.4 years. CONCLUSIONS: Recent advancements in catheter technology have facilitated MT in pediatric patients. Pediatric MT appears to be safe and effective for treating cerebral large vessel occlusions; however, technical limitations can arise secondary to small vessel diameters. A technical guide based on patient age and femoral artery diameter is provided.
- 1 July 2026
- Published by Wolters Kluwer Health in Stroke: Vascular and Interventional Neurology
- Vol. 6 (4)
Open AccessMechanical Thrombectomy for Pediatric Acute Ischemic Stroke With Large Vessel Occlusion: Technical Guide and Case Series
BACKGROUND: Pediatric acute ischemic stroke is a rare entity, and mechanical thrombectomy (MT) in this population can be technically challenging. We aim to discuss key technical aspects of pediatric MT and report our experience in this population. METHODS: Pediatric patients were identified from our prospectively maintained database of MT patients. Inclusion criteria were pediatric patients’ age >28 days and <18 years undergoing MT for large vessel occlusion at a single center between 2012 and 2023. RESULTS: Seven patients were included in this case series. Patient age ranged from ≈1 to 17 (10.0±6.2) years. Causes of large vessel occlusion included hypercoagulability disorders, cardiac disorders, and iatrogenic during neurointerventions. Most patients (n=5, 71.4%) had middle cerebral artery or internal carotid artery occlusions. Six patients (85.7%) were successfully treated with MT, achieving modified Thrombolysis in Cerebral Infarction grade 2C or above. Five patients were treated with stent retriever MT and the other 2 patients with aspiration MT alone, with an average of 2.3±1.5 passes total. Five patients (71.4%) made an excellent clinical recovery with a pediatric modified Rankin Scale score ≤2 at last outpatient follow-up (pediatric modified Rankin Scale score, 1.8±1.2). Average follow-up duration was 2.7±2.4 years. CONCLUSIONS: Recent advancements in catheter technology have facilitated MT in pediatric patients. Pediatric MT appears to be safe and effective for treating cerebral large vessel occlusions; however, technical limitations can arise secondary to small vessel diameters. A technical guide based on patient age and femoral artery diameter is provided.
- Open Access
- 27 April 2026
- Published by MDPI AG in Journal of Vascular Diseases
- Vol. 5 (3) , 20
Mechanical Thrombectomy with the Vecta 46 Catheter: A Safety and Outcome Analysis
Objective: The AXS Vecta 46 intermediate catheter (Stryker) features a large inner diameter, enabling effective aspiration, combined with a small outer diameter and soft distal-tip flexibility, which allows for safe tracking through more tortuous and smaller arterial segments to target medium vessel occlusions non-traumatically. The efficacy of the Vecta 46 in the spectrum of large and medium vessel occlusions has not been well elucidated in the literature. Methods: This retrospective cohort study included patients who underwent MT for acute ischemic stroke at our institution between July 2022 and June 2024. The outcomes of patients treated with Vecta 46 were compared to those of all other catheters used at the institution. Results: The distribution of aspiration and stent retriever attempts in Vecta 46 procedures versus non-Vecta 46 procedures was significantly different (p = 0.00325). Aspiration was attempted 1.66 ± 0.936 times in the Vecta 46 group and 1.12 ± 0.650 times in the non-Vecta 46 group (p = 0.00135). More mechanical thrombectomies with the Vecta 46 included aspiration of a secondary thrombus (p = 0.0314), despite no difference in the distribution of the primary or secondary occlusion location. There were no statistically significant differences in recanalization success (p = 0.800), recanalization time (p = 0.245), procedure duration (p = 0.580), discharge modified Rankin Score (p = 0.875), or intracranial hemorrhage rate (p = 0.720) between non-Vecta 46 and Vecta 46 procedures. Conclusions: Vecta 46 has similar safety and functional outcomes compared to other endovascular treatment options despite procedural differences.
- 27 April 2026
- Published by MDPI AG in Journal of Vascular Diseases
- Vol. 5 (3) , 20
Open AccessMechanical Thrombectomy with the Vecta 46 Catheter: A Safety and Outcome Analysis
Objective: The AXS Vecta 46 intermediate catheter (Stryker) features a large inner diameter, enabling effective aspiration, combined with a small outer diameter and soft distal-tip flexibility, which allows for safe tracking through more tortuous and smaller arterial segments to target medium vessel occlusions non-traumatically. The efficacy of the Vecta 46 in the spectrum of large and medium vessel occlusions has not been well elucidated in the literature. Methods: This retrospective cohort study included patients who underwent MT for acute ischemic stroke at our institution between July 2022 and June 2024. The outcomes of patients treated with Vecta 46 were compared to those of all other catheters used at the institution. Results: The distribution of aspiration and stent retriever attempts in Vecta 46 procedures versus non-Vecta 46 procedures was significantly different (p = 0.00325). Aspiration was attempted 1.66 ± 0.936 times in the Vecta 46 group and 1.12 ± 0.650 times in the non-Vecta 46 group (p = 0.00135). More mechanical thrombectomies with the Vecta 46 included aspiration of a secondary thrombus (p = 0.0314), despite no difference in the distribution of the primary or secondary occlusion location. There were no statistically significant differences in recanalization success (p = 0.800), recanalization time (p = 0.245), procedure duration (p = 0.580), discharge modified Rankin Score (p = 0.875), or intracranial hemorrhage rate (p = 0.720) between non-Vecta 46 and Vecta 46 procedures. Conclusions: Vecta 46 has similar safety and functional outcomes compared to other endovascular treatment options despite procedural differences.
- Open Access
Thoughts and Therapies: Melanoma Brain Metastases
Brain metastases are the third most common metastatic site in melanoma patients, with 40% of melanoma patients developing melanoma brain metastasis (MBM). Symptomology of MBM ranges from headaches, neurological deficits, cognitive changes, and seizures, resulting from MBM embedding in areas of highest blood flow following the breakdown of the blood–brain barrier (BBB) via genetic, cytokine, and molecular processes. The BBB is highly restrictive, making MBM difficult to treat. Challenges in MBM treatment are evident in adverse therapeutic effects, such as neurocognitive decline with whole-brain radiation therapy (WBRT), increased risk of radiation necrosis with stereotactic radiosurgery (SRS), and reduced penetration into the brain, which can lead to drug resistance with prolonged use of MAPK inhibitors. This review investigates current and novel treatments against MBM, including radiotherapy, chemotherapy, targeted therapies such as BRAF/MAPK inhibitors, and immunotherapy.
Open AccessThoughts and Therapies: Melanoma Brain Metastases
Brain metastases are the third most common metastatic site in melanoma patients, with 40% of melanoma patients developing melanoma brain metastasis (MBM). Symptomology of MBM ranges from headaches, neurological deficits, cognitive changes, and seizures, resulting from MBM embedding in areas of highest blood flow following the breakdown of the blood–brain barrier (BBB) via genetic, cytokine, and molecular processes. The BBB is highly restrictive, making MBM difficult to treat. Challenges in MBM treatment are evident in adverse therapeutic effects, such as neurocognitive decline with whole-brain radiation therapy (WBRT), increased risk of radiation necrosis with stereotactic radiosurgery (SRS), and reduced penetration into the brain, which can lead to drug resistance with prolonged use of MAPK inhibitors. This review investigates current and novel treatments against MBM, including radiotherapy, chemotherapy, targeted therapies such as BRAF/MAPK inhibitors, and immunotherapy.
- 25 March 2026
- Published by Wolters Kluwer Health in Neurosurgery
- Vol. 99 (6) , 1470-1480
Hourly Neurological Examinations After Nontraumatic, Vascular Acute Brain Injury Associated With Delirium: A Retrospective Cohort Study
BACKGROUND AND OBJECTIVES: Hourly neurological examinations are commonly performed in neurocritical care units after acute brain injury to detect clinical deterioration. However, their clinical yield and impact on patient outcomes, particularly delirium, remain unclear. Our objective is to evaluate the diagnostic utility of hourly neurological examinations and their association with delirium in patients with nontraumatic, vascular acute brain injury. METHODS: We conducted a retrospective observational study of patients admitted to the neuro-ICU between January 2022 and December 2024 with nontraumatic, vascular acute brain injury (large vessel occlusion stroke, subarachnoid hemorrhage, or spontaneous intracerebral hemorrhage). We analyzed the duration and frequency of hourly neurological examinations, the incidence of neurological decline, the use of radiographic imaging or electrophysiological testing, and the occurrence of delirium. Statistical comparisons were made using the unpaired Student t -tests, Mann–Whitney U tests, and multivariate logistic regression. RESULTS: Of 191 patients (mean age 63.3 ± 15.0 years; 53.0% female), 51.0% developed delirium. Across 34 767 total hours of hourly examinations, 600 neurological declines (1.7%) were detected. Most declines (73.1%) required no further imaging, electrophysiological testing, or neurosurgical intervention; only 6.0% led to neurosurgical intervention. No neurosurgical procedures or changes in clinical management were triggered by examinations between 84 and 108 hours postadmission. Delirium was significantly associated with longer duration of hourly examinations across the total cohort ( P < .001) and spontaneous intracerebral hemorrhage subgroup ( P < .001) and approached significance in aneurysmal subarachnoid hemorrhage group ( P = .056) but not in large vessel occlusion strokes ( P = .176). CONCLUSION: Hourly neurological examinations after acute brain injury detect few actionable events after 48 hours of admission and are associated with increased delirium, particularly in intracerebral hemorrhage patients. These findings suggest a need for prospective studies to assess the utility and duration of routine hourly examinations in acutely brain-injured patients.
- 25 March 2026
- Published by Wolters Kluwer Health in Neurosurgery
- Vol. 99 (6) , 1470-1480
Hourly Neurological Examinations After Nontraumatic, Vascular Acute Brain Injury Associated With Delirium: A Retrospective Cohort Study
BACKGROUND AND OBJECTIVES: Hourly neurological examinations are commonly performed in neurocritical care units after acute brain injury to detect clinical deterioration. However, their clinical yield and impact on patient outcomes, particularly delirium, remain unclear. Our objective is to evaluate the diagnostic utility of hourly neurological examinations and their association with delirium in patients with nontraumatic, vascular acute brain injury. METHODS: We conducted a retrospective observational study of patients admitted to the neuro-ICU between January 2022 and December 2024 with nontraumatic, vascular acute brain injury (large vessel occlusion stroke, subarachnoid hemorrhage, or spontaneous intracerebral hemorrhage). We analyzed the duration and frequency of hourly neurological examinations, the incidence of neurological decline, the use of radiographic imaging or electrophysiological testing, and the occurrence of delirium. Statistical comparisons were made using the unpaired Student t -tests, Mann–Whitney U tests, and multivariate logistic regression. RESULTS: Of 191 patients (mean age 63.3 ± 15.0 years; 53.0% female), 51.0% developed delirium. Across 34 767 total hours of hourly examinations, 600 neurological declines (1.7%) were detected. Most declines (73.1%) required no further imaging, electrophysiological testing, or neurosurgical intervention; only 6.0% led to neurosurgical intervention. No neurosurgical procedures or changes in clinical management were triggered by examinations between 84 and 108 hours postadmission. Delirium was significantly associated with longer duration of hourly examinations across the total cohort ( P < .001) and spontaneous intracerebral hemorrhage subgroup ( P < .001) and approached significance in aneurysmal subarachnoid hemorrhage group ( P = .056) but not in large vessel occlusion strokes ( P = .176). CONCLUSION: Hourly neurological examinations after acute brain injury detect few actionable events after 48 hours of admission and are associated with increased delirium, particularly in intracerebral hemorrhage patients. These findings suggest a need for prospective studies to assess the utility and duration of routine hourly examinations in acutely brain-injured patients.
- Open Access
- 22 December 2025
- Published by Baishideng Publishing Group Inc. in World Journal of Gastrointestinal Pathophysiology
- Vol. 16 (4)
Colorectal cancer metastasis to the brain: A scoping review of incidence, treatment, and outcomes
BACKGROUND Over 150000 new diagnoses of colorectal cancer (CRC) are diagnosed yearly, and 1 in 5 patients have distant metastases on diagnosis. Previous estimates approximate that brain metastases (BM) occur in 0.6% to 3.2% of patients with CRC. AIM To describe the updated literature about the incidence and risk factors of BM in CRC as well as their treatment with surgery, chemotherapy, and radiation. METHODS We systematically searched the literature published between January 1, 2010 and April 1, 2025 in PubMed, Cochrane, Scopus, and EMBASE. All studies about BM from CRC were included. Studies only containing information about the treatment of primary CRC or primary brain tumors were not included. Articles were categorized and described as incidence, surgery, chemotherapy, or radiation to provide an overview of the state of research on BM from CRC. RESULTS Our primary search resulted in 1648 articles that were eventually screened to 147. These articles were analyzed to provide the state of current literature on incidence and risk factors of BM from CRC as well as how these metastases are treated with chemotherapy, radiation, and surgery. CONCLUSION Prognosis is influenced by tumor burden, performance status, and emerging molecular markers. Stereotactic radiotherapy and surgical resection provide favorable outcomes for select patients, whereas chemotherapy and immunotherapy remain areas of limited evidence. Continued research is needed to identify high-risk patients and optimize multidisciplinary treatment approaches.
- 22 December 2025
- Published by Baishideng Publishing Group Inc. in World Journal of Gastrointestinal Pathophysiology
- Vol. 16 (4)
Open AccessColorectal cancer metastasis to the brain: A scoping review of incidence, treatment, and outcomes
BACKGROUND Over 150000 new diagnoses of colorectal cancer (CRC) are diagnosed yearly, and 1 in 5 patients have distant metastases on diagnosis. Previous estimates approximate that brain metastases (BM) occur in 0.6% to 3.2% of patients with CRC. AIM To describe the updated literature about the incidence and risk factors of BM in CRC as well as their treatment with surgery, chemotherapy, and radiation. METHODS We systematically searched the literature published between January 1, 2010 and April 1, 2025 in PubMed, Cochrane, Scopus, and EMBASE. All studies about BM from CRC were included. Studies only containing information about the treatment of primary CRC or primary brain tumors were not included. Articles were categorized and described as incidence, surgery, chemotherapy, or radiation to provide an overview of the state of research on BM from CRC. RESULTS Our primary search resulted in 1648 articles that were eventually screened to 147. These articles were analyzed to provide the state of current literature on incidence and risk factors of BM from CRC as well as how these metastases are treated with chemotherapy, radiation, and surgery. CONCLUSION Prognosis is influenced by tumor burden, performance status, and emerging molecular markers. Stereotactic radiotherapy and surgical resection provide favorable outcomes for select patients, whereas chemotherapy and immunotherapy remain areas of limited evidence. Continued research is needed to identify high-risk patients and optimize multidisciplinary treatment approaches.
- Open Access
Mechanical thrombectomy with the Vecta 46 catheter: a safety and outcome analysis
2. Background: The AXS Vecta 46 intermediate catheter (Stryker) provides a large enough inner diameter to achieve effective aspiration with a small enough outer diameter and soft distal-tip flexibility to track safely through more tortuous and smaller arterial segments to non-traumatically target medium vessel occlusions. The efficacy of the Vecta 46 in the spectrum of large and medium vessel occlusions has not been well elucidated in the literature. Methods: This retrospective cohort study included patients who underwent MT for acute ischemic stroke at the University of Florida between July 2022 and June 2024. The outcomes of patients treated with the Vecta 46 was compared to that of all other catheters used at the institution. Results: The distribution of aspiration and stent retriever attempts in Vecta 46 procedures versus non-Vecta 46 procedures was significantly different (p = 0.00325). Aspiration was attempted 1.66 ± 0.936 times in the Vecta 46 group and 1.12 ± 0.650 times in the non-Vecta 46 group (p = 0.00135). More mechanical thrombectomies with the Vecta 46 included aspiration of a secondary thrombus (p = 0.0314), despite no difference in distribution of primary or secondary occlusion location. There were no statistically significant differences in recanalization success (p = 0.800), recanalization time (p = 0.245), procedure duration (p = 0.580), discharge modified Rankin Score (p = 0.875), or intracranial hemorrhage rate (p = 0.720) between non-Vecta 46 and Vecta 46 procedures. Conclusions: Vecta 46 has similar safety and functional outcomes compared to other endovascular treatment options despite procedural differences.
Open AccessMechanical thrombectomy with the Vecta 46 catheter: a safety and outcome analysis
2. Background: The AXS Vecta 46 intermediate catheter (Stryker) provides a large enough inner diameter to achieve effective aspiration with a small enough outer diameter and soft distal-tip flexibility to track safely through more tortuous and smaller arterial segments to non-traumatically target medium vessel occlusions. The efficacy of the Vecta 46 in the spectrum of large and medium vessel occlusions has not been well elucidated in the literature. Methods: This retrospective cohort study included patients who underwent MT for acute ischemic stroke at the University of Florida between July 2022 and June 2024. The outcomes of patients treated with the Vecta 46 was compared to that of all other catheters used at the institution. Results: The distribution of aspiration and stent retriever attempts in Vecta 46 procedures versus non-Vecta 46 procedures was significantly different (p = 0.00325). Aspiration was attempted 1.66 ± 0.936 times in the Vecta 46 group and 1.12 ± 0.650 times in the non-Vecta 46 group (p = 0.00135). More mechanical thrombectomies with the Vecta 46 included aspiration of a secondary thrombus (p = 0.0314), despite no difference in distribution of primary or secondary occlusion location. There were no statistically significant differences in recanalization success (p = 0.800), recanalization time (p = 0.245), procedure duration (p = 0.580), discharge modified Rankin Score (p = 0.875), or intracranial hemorrhage rate (p = 0.720) between non-Vecta 46 and Vecta 46 procedures. Conclusions: Vecta 46 has similar safety and functional outcomes compared to other endovascular treatment options despite procedural differences.
- Open Access
- 15 October 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (20) , 10053
Molecular Targets for Intracranial Aneurysm Treatment
Intracranial aneurysms (IAs) are a common cerebrovascular pathology with deadly potential. Neurointerventionalists commonly treat IAs with endovascular coiling, minimizing procedural risk at the cost of an increased recurrence rate. New therapies for reducing the rate of coiled and uncoiled IA growth and rupture would help reduce the morbidity and mortality patients experience when IAs rupture. Hemodynamic shear stress drives IA formation through molecular mechanisms, generating damage-associated molecular proteins (DAMPs), which lead to inflammation and extracellular matrix remodeling. Nuclear factor κB (NF-κB) and interleukin-6 (IL-6) maintain an inflammatory environment in IA walls, generating immune-cell chemotactic proteins, such as monocyte chemoattractant protein-1 (MCP-1) and IL-8. These molecules play a complex role in IAs, being important for IA formation and IA healing. Vascular smooth muscle cells and infiltrated immune cells secrete matrix metalloproteinases (MMPs), which initiate extracellular matrix remodeling. Tissue inhibitors of matrix metalloproteinases (TIMPs) balance this remodeling. The increased MMP to TIMP ratio is characteristic of IA progression, making these molecules important targets for IA therapies. Endothelial dysfunction generates nitric oxide and other reactive oxygen species, which exacerbate inflammation and cell death in IA walls. A better understanding of molecular mechanisms underlying IA formation, progression, and rupture will allow researchers to develop molecular IA therapies.
- 15 October 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (20) , 10053
Open AccessMolecular Targets for Intracranial Aneurysm Treatment
Intracranial aneurysms (IAs) are a common cerebrovascular pathology with deadly potential. Neurointerventionalists commonly treat IAs with endovascular coiling, minimizing procedural risk at the cost of an increased recurrence rate. New therapies for reducing the rate of coiled and uncoiled IA growth and rupture would help reduce the morbidity and mortality patients experience when IAs rupture. Hemodynamic shear stress drives IA formation through molecular mechanisms, generating damage-associated molecular proteins (DAMPs), which lead to inflammation and extracellular matrix remodeling. Nuclear factor κB (NF-κB) and interleukin-6 (IL-6) maintain an inflammatory environment in IA walls, generating immune-cell chemotactic proteins, such as monocyte chemoattractant protein-1 (MCP-1) and IL-8. These molecules play a complex role in IAs, being important for IA formation and IA healing. Vascular smooth muscle cells and infiltrated immune cells secrete matrix metalloproteinases (MMPs), which initiate extracellular matrix remodeling. Tissue inhibitors of matrix metalloproteinases (TIMPs) balance this remodeling. The increased MMP to TIMP ratio is characteristic of IA progression, making these molecules important targets for IA therapies. Endothelial dysfunction generates nitric oxide and other reactive oxygen species, which exacerbate inflammation and cell death in IA walls. A better understanding of molecular mechanisms underlying IA formation, progression, and rupture will allow researchers to develop molecular IA therapies.
- Open Access
- 13 October 2025
- Published by Wolters Kluwer Health in Neurosurgery Practice
- Vol. 6 (4)
Patient Follow-up After Endovascular Treatment of Cerebral Aneurysms: Identifiable Barriers and Implications for Treatment Decisions
BACKGROUND AND OBJECTIVES: Cerebral aneurysms are the major cause of spontaneous subarachnoid hemorrhage, and a common treatment is endovascular embolization. Aneurysmal recurrence after embolization is frequent, and clinical follow-up to monitor for this is critical to prevent subarachnoid hemorrhage. Herein, we assess demographic and socioeconomic factors associated with poor clinical follow-up to determine which patients are at high risk of loss to follow-up. METHODS: A retrospective analysis was performed of 937 patients who underwent endovascular treatment of cerebral aneurysms at a single center from 2006 to 2017. Attendance at follow-up visits for 5 years after treatment was correlated with various demographic and socioeconomic factors. Follow-up for patients who initially presented with unruptured vs ruptured aneurysms was also compared. RESULTS: The most significant factors associated with poor follow-up were lack of insurance and non–English-speaking status. Noninsured patients had significantly less follow-up in both mean number of follow-up visits (2.5 ± 1.7 visits for insured patients and 1.0 ± 1.2 visits for noninsured, P < .0001), and in time until lost to follow-up (2.9 ± 1.9 years for insured and 1.1 ± 1.4 years for non-insured, P < .0001). Non–English-speaking patients had less follow-up visits (2.3 ± 1.7 visits for English-speaking and 0.74 ± 1.0 visits for non–English-speaking, P < .0001) and were more quickly lost to follow-up (2.6 ± 1.9 years for English-speaking and 0.82 ± 1.2 years for non–English-speaking, P < .0001). CONCLUSION: Demographics and socioeconomic factors, particularly lack of insurance and non–English-speaking status, are correlated with poor clinical follow-up after endovascular treatment of cerebral aneurysms. Patients at high risk of loss to follow-up should be counseled before treatment about risk of aneurysm recurrence.
- 13 October 2025
- Published by Wolters Kluwer Health in Neurosurgery Practice
- Vol. 6 (4)
Open AccessPatient Follow-up After Endovascular Treatment of Cerebral Aneurysms: Identifiable Barriers and Implications for Treatment Decisions
BACKGROUND AND OBJECTIVES: Cerebral aneurysms are the major cause of spontaneous subarachnoid hemorrhage, and a common treatment is endovascular embolization. Aneurysmal recurrence after embolization is frequent, and clinical follow-up to monitor for this is critical to prevent subarachnoid hemorrhage. Herein, we assess demographic and socioeconomic factors associated with poor clinical follow-up to determine which patients are at high risk of loss to follow-up. METHODS: A retrospective analysis was performed of 937 patients who underwent endovascular treatment of cerebral aneurysms at a single center from 2006 to 2017. Attendance at follow-up visits for 5 years after treatment was correlated with various demographic and socioeconomic factors. Follow-up for patients who initially presented with unruptured vs ruptured aneurysms was also compared. RESULTS: The most significant factors associated with poor follow-up were lack of insurance and non–English-speaking status. Noninsured patients had significantly less follow-up in both mean number of follow-up visits (2.5 ± 1.7 visits for insured patients and 1.0 ± 1.2 visits for noninsured, P < .0001), and in time until lost to follow-up (2.9 ± 1.9 years for insured and 1.1 ± 1.4 years for non-insured, P < .0001). Non–English-speaking patients had less follow-up visits (2.3 ± 1.7 visits for English-speaking and 0.74 ± 1.0 visits for non–English-speaking, P < .0001) and were more quickly lost to follow-up (2.6 ± 1.9 years for English-speaking and 0.82 ± 1.2 years for non–English-speaking, P < .0001). CONCLUSION: Demographics and socioeconomic factors, particularly lack of insurance and non–English-speaking status, are correlated with poor clinical follow-up after endovascular treatment of cerebral aneurysms. Patients at high risk of loss to follow-up should be counseled before treatment about risk of aneurysm recurrence.
- Open Access
- 12 June 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (6) , 1452
Emerging Chemotherapy Targets: Insights from Advances in Glioma Treatment
Primary brain tumors represent a significant focus of contemporary research. With advancements in technology and the increasing detection of cases through novel diagnostic methods, innovative therapies and approaches to chemotherapy continue to emerge. The paper explores recent advancements in chemotherapy for glioblastoma, highlighting innovative approaches that provide valuable mechanistic insights. It delves into the mechanisms of action, molecular targets, and the future potential of emerging therapies for gliomas. Additionally, this paper offers an overview investigating a range of therapies, including various chemotherapeutic agents, CAR-T cell therapies, drugs targeting cellular respiration, and other approaches. Furthermore, the paper addresses chemotherapy-related challenges, including the blood–brain barrier, drug resistance, and immunosuppression, while proposing potential solutions to overcome these obstacles.
- 12 June 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (6) , 1452
Open AccessEmerging Chemotherapy Targets: Insights from Advances in Glioma Treatment
Primary brain tumors represent a significant focus of contemporary research. With advancements in technology and the increasing detection of cases through novel diagnostic methods, innovative therapies and approaches to chemotherapy continue to emerge. The paper explores recent advancements in chemotherapy for glioblastoma, highlighting innovative approaches that provide valuable mechanistic insights. It delves into the mechanisms of action, molecular targets, and the future potential of emerging therapies for gliomas. Additionally, this paper offers an overview investigating a range of therapies, including various chemotherapeutic agents, CAR-T cell therapies, drugs targeting cellular respiration, and other approaches. Furthermore, the paper addresses chemotherapy-related challenges, including the blood–brain barrier, drug resistance, and immunosuppression, while proposing potential solutions to overcome these obstacles.